2022-500618-24-00RecruitingPhase 4
Prostate medication, metabolism and gut microbiota, PROMED.
Source: EU CTIS (euclinicaltrials.eu) · Last updated 4 Oct 2022 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The general aim is to understand the interaction of prostate medical therapies and gut microbiota. Main objective is to investigate how prostate medical therapies (5-ARI, ADT) affect gut microbiota composition.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 2 Jun 2022
- Start date
- 1 Dec 2022
- Lead sponsor
- Turku University Central Hospital
- Diseases
- Prostate cancer
- EU CT number
- 2022-500618-24-00
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 100
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Age
- age < 18 years
Other
- inability to comply with study procedures or unwillingness to participate in the study
Who the study is looking for
- histologically confirmed prostate cancer or benign prostate hyperplasia
- provision of signed and dated informed consent form
- ability and stated willingness to comply with all study procedures and availablity for the duration of the study
- male aged >18 years
Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Turku University Central Hospital | Turku | Finland | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.